14 minutes | Jul 17th 2020

Lenvatinib Plus Pembrolizumab for Patients With Advanced Gastric Cancer

This week, we’ll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We’ll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we’ll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.

Coverage of stories discussed this week on ascopost.com:

Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer

USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

Play Next
Mark Played